tbuckley/cabot-search huggingface dataset:
Combination therapy with arsenic trioxide (ATO), all-trans retinoic acid (ATRA), and gemtuzumab ozogamycin (GO) in relapsed acute promyelocytic leukemia (APL)
Authors: A. M. Aribi, H. Kantarjian, E. Estey, E. Freireich, C. Koller, D. Thomas, S. Kornblau, S. Faderl, N. Laddie, G. Garcia-Manero, J. Cortes
Journal: Journal of Clinical Oncology (2006)

6558 Background: Relapse occurs in 20 to 30% of patients with APL treated with ATRA. ATO is an effective agent for salvage of APL relapse, and GO has shown activity in APL due to the high expression of CD33. Methods: We investigated the efficacy of a combination regimen of ATO, ATRA and mylotarg in 8 patients with APL in 1st relapse. All patients had been previously treated with regimens that included ATRA and chemotherapy. Patients received ATO 0.15 mg/kg intravenously until marrow complete remission (CR). Once in marrow CR patient was observed until CR. Once CR was achieved or 60 days from the start of induction therapy, consolidation therapy was initiated with 1) ATO 0.15 mg/kg intravenously for 5 days per week for 4 weeks, repeated every 8 weeks for total of 5 courses, 2) ATRA 45mg/m 2 orally twice daily 10 days per month for 10 months, and 3) GO 9 mg/m 2 intravenously monthly for 10 months. Patients then received maintenance with 1) idarubicin 8mg/m 2 daily on day 1 and 2 every month for 3 months, 2) ATRA 45mg/m 2 orally daily 10 days per month for 14 months, 3) 6-MP 50 mg orally 3 times per day for 11 months and methotrexate 15mg/m 2 orally once a week for 11 months. Results: The median age is 51years (range, 18–68 years), median WBC count 1.9 ×10 9 /L (range 0.9–7.7 ×10 9 /L), platelets 71 ×10 9 /L (range, 6–164 ×10 9 /L). The median duration of 1st CR was 7 months (range, 3 to 17 months). Seven patients achieved CR with median time to remission of 8 weeks (range 3–15 weeks). One patient achieved marrow CR after 3 weeks of therapy but is too early to evaluate for CR. All 7 are still in CR after a median follow up of 36 + months (range, 1 + to 51 + months). All seven patients achieved molecular remission. All patients had myelosuppression but there was no grade 3–4 extramedullary toxicity. Two patients died, one died secondary to complication related to metastatic lung adenocarcinoma, and the other patient died of sepsis. Conclusions: We concluded that the combination of ATO, ATRA and mylotarg is effective and may achieve durable remissions in many patients with APL in first relapse. It should be considered as an effective alternative to allogeneic or autologous transplant. No significant financial relationships to disclose.
PAPEL DE LA ENDOSCOPIA DE AMPLIO ESPECTRO EN EL CRIBADO DE CÁNCER COLO-RECTAL: ENSAYO ALEATORIZADO
Authors: MH Núñez Rodríguez, P Diez Redondo, M Cimavilla, J Santos, M De Benito, R Sanchez-Ocaña, R Torres, C De La Serna Higuera, P Gil Simon, M Pérez- Miranda Castillo
Journal: Endoscopy (2016)

La colonoscopia es el método oro para prevenir el cancer colorectal (CCR) al detectar lesiones precursoras y permitir resecarlas, sin embargo entre el 22 y 28% de las lesiones no se detectan durante una colonoscopia lo que conlleva a la aparición de cánceres de intervalo.
TCT-399 Impact of post-dilatation on angiographic and clinical outcomes of patients undergoing bioresorbable scaffold implantation in clinical practice
Authors: Jens Wiebe, Yukinori Harada, Petra Hoppmann, Roisin Colleran, Sebastian Kufner, Salvatore Cassese, Erion Xhepa, Tobias Rheude, Daniele Giacoppo, Tareq Ibrahim, Karl-Ludwig Laugwitz, Adnan Kastrati, Robert Byrne
Journal: Journal of the American College of Cardiology (2016)
TCT-654 Risk of Readmission for Acute Heart Failure, Subsequent Readmission, and Mortality Following Transcatheter Aortic Valve Replacement: An Analysis from PARTNER 1
Authors: John Petersen, Eugene H. Blackstone, Jeevanantham Rajeswaran, David Cohen, Pamela Douglas, Rebecca Hahn, Susheel Kodali, Lars Svensson, Martin Leon
Journal: Journal of the American College of Cardiology (2016)
Healthcare professionals must “think globally, act locally” on climate change
Authors: Gee Yen Shin, Rohini J Manuel
Journal: BMJ (2016)

We agree with Ramanathan and Haines about the harmful effects of short lived climate pollutants and carbon dioxide on climate change.1 We also agree that if unchecked, climate change poses a grave threat to global public health.

Although we concur that healthcare professionals should be active …
PS01.25: Large Cell Neuroendocrine Carcinoma of the Lung: Prognostic Factors of Survival and Recurrence After R0 Surgical Resection
Authors: Maria Cattoni, Eric Vallieres, Lisa M. Brown, Amir A. Sarkeshik, Stefano Margaritora, Alessandra Siciliani, Pier Luigi Filosso, Francesco Guerrera, Andrea Imperatori, Nicola Rotolo, Farhood Farjah, Grace Wandell, Kimberly Costas, Catherine Mann, Michal Hubka, Stephen Kaplan, Alexander S. Farivar, Ralph W. Aye, Brian Louie
Journal: Journal of Thoracic Oncology (2016)
TCT-562 Impact of Serum LDL and Statin Therapy on Coronary Plaque Morphology: An OCT and IVUS Co-registered Study
Authors: Yang Cao, Gary Mintz, Mitsuaki Matsumura, W.E.N.B.I.N. ZHANG, Cheolmin Lee, Tsunekazu Kakuta, Akiko Maehara
Journal: Journal of the American College of Cardiology (2016)
Ebola: Anatomy of an Epidemic
Authors: Terrence Q. Lo, Barbara J. Marston, Benjamin A. Dahl, Kevin M. De Cock
Journal: Annual Review of Medicine (2016)

As of the end of March 2016, the West Africa epidemic of Ebola virus disease (Ebola) had resulted in a total of 28,646 cases, 11,323 of them fatal, reported to the World Health Organization. Guinea, Liberia, and Sierra Leone were most heavily affected, but Ebola cases were exported to several other African and European countries as well as the United States, with limited further transmission, including to healthcare workers. We review the descriptive epidemiology of the outbreak, novel aspects and insights concerning the unprecedented response, scientific observations, and public health implications. The large number of Ebola survivors has highlighted the frequency of persistent symptoms and the possibility of virus persistence in sanctuary sites, sometimes leading to delayed transmission. Although transmission appears to have ceased in 2016, the West Africa Ebola epidemic has profoundly influenced discussions and practice concerning global health security.
TCT-744 New generation devices for transfemoral transcatheter aortic valve replacement (Boston Scientific Lotus Valve and Edwards Sapien 3) are superior compared with last generation devices (Edwards XT and Medtronic Corevalve) with respect to VARC-2 outcome
Authors: Julia Seeger, Birgid Gonska, Christoph Rodewald, Wolfgang Rottbauer, Jochen Wöhrle
Journal: Journal of the American College of Cardiology (2016)
Overdiagnosis of Coronary Artery Disease Detected by Coronary Computed Tomography Angiography
Authors: Torrey Schmidt, Ronald Maag, Andrew J. Foy
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Donor/Recipient Mixed Chimerism Does Not Predict Graft Failure in Children with Beta-Thalassemia Given Allogeneic Cord Blood Transplantation from An HLA-Identical Related Donor
Authors: Daniela Lisini, Marco Zecca, Giovanna Giorgiani, Daniela Montagna, Rosaria Cristantielli, Massimo Labirio, Pierangela Grignani, Carlo Previderé, Giovanni Amendola, Angela Mastronuzzi, Rita Maccario, Franco Locatelli
Journal: Blood (2008)
P85 A Composite Index of Saturation and Distance Walked during a 6-Minute Walk Test (6MWT): A retrospective methodological comparison: Abstract P85 Table 1
Authors: R Brown, AH Kendrick
Journal: Thorax (2015)

<h3>Background</h3> The 6MWT is a simple, reproducible test of exercise performance. Lettieri <i>et al.</i><sup>1</sup> proposed a composite index of the product of the lowest oxygen saturation (SpO<sub>2</sub>) and distanced walked – the distance–saturation product (DSP). Pimenta <i>et al.</i><sup>2</sup> calculated the differences between actual SpO<sub>2 </sub>and 100% every two seconds, and produced the desaturation-distance ratio (DDR-1). Ijiri <i>et al.</i><sup>3</sup> simplified Pimenta’s methodology, using the SpO<sub>2</sub> at the end of each minute (DDR-2). <h3>Aim</h3> To compare the different methods of calculating the composite index. <h3>Methods</h3> We retrospectively analysed 48 6MWT datasets, obtained using standard methodology. SpO<sub>2</sub> was recorded every second using a Minolta 300i pulse oximeter and analysed using Visi-Download (Stowood Scientific, Oxford). The DSP and DDR’s was calculated by each method. Additionally, data using Pimenta’s method, was calculated using one second data intervals (DDR-3). Data are given as median (IQR). <h3>Results</h3> 41/48 patients were male. Group age was 63 (53 to 73) years, FEV<sub>1</sub>%pred 68.4% (41.3 to 82.3), distance walked 390 m (321.3 to 477.5), baseline SpO<sub>2</sub> 95% (93 to 96) and decline in SpO<sub>2</sub> was -4% (-2 to -8). DSP was 324.6 (278.8 to 419.4) m%, DDR-1 was 8.90 (4.98 to 13.27), DDR-2 was 16.83 (9.14 to 24.8) and DDR-3 was 8.90 (4.99 to 13.66). Bland-Altman analysis of DDR-1 vs DDR-3 gave a bias of -0.0083 and 95% limits of -0.042 to 0.025. Correlations between each index and FEV<sub>1</sub>%pred, SpO<sub>2</sub> and Borg were significant for FEV<sub>1</sub>%pred and SpO<sub>2</sub>, but not significant for Borg (Table 1). <h3>Conclusions</h3> 1) there is no significant difference between DDR-1 and DDR-3, both providing an accurate assessment of changes in SpO<sub>2</sub> during exercise and allowing for the different storage capabilities of pulse oximeters; 2) the simplest index (DSP), showed poorer correlations cpmpared to the DDR’s, perhaps reflecting the simplicity of the index; 3) the conceptual idea of a composite index of distance walked and changes in SpO<sub>2</sub> during a 6MWT needs further investigation in a range of different clinical settings. <h3>References</h3> 1 Lettieri CJ, Nathan SD, Browning RF, <i>et al</i>. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. <i>Respir Med</i>. 2006;<b>100</b>:1734–1741 2 Pimenta SP, Rocha RB, Baldi BG, <i>et al</i>.<i> Clinics</i> 2010;<b>65</b>:841–846 3 Ijiri N, Kanazawa H, Yoshikawa T, Hirata K, <i>et al</i>. Application of a new parameter in the 6-minute walk test for manifold analysis of exercise capacity in patients with COPD. <i>Int J Chron Obstruct Pulmon Dis</i>. 2014;<b>9</b>:1235–1240
TCT-102 Association Between Operator Experience with Access Type in Percutaneous Coronary Intervention and Outcomes in Patients with Acute Coronary Syndrome: A Network Meta-Analysis of Randomized Controlled Trials
Authors: Rahman Shah, Inyong Hwang Hwang, Mannu Nayyar, Ellis Christian, Kodangudi Ramanathan, Abdul Rashid
Journal: Journal of the American College of Cardiology (2016)
TCT-289 Comparison of Various Scores for Predicting Success and Efficiency of Chronic Total Occlusion Percutaneous Coronary Intervention
Authors: Aris Karatasakis, Barbara Anna Danek, Dimitri Karmpaliotis, Khaldoon Alaswad, Farouc Jaffer, Robert Yeh, Mitul Patel, John Bahadorani, William Lombardi, R. Michael Wyman, J. Aaron Grantham, David Kandzari, Nicholas Lembo, Anthony Doing, Catalin Toma, Jeffrey Moses, Ajay Kirtane, Manish Parikh, Ziad Ali, Santiago Garcia, Pratik Kalsaria, Judit Karacsonyi, Aya Alame, Craig Thompson, Subhash Banerjee, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2016)
TCT-466 Bioresorbable Polymer Coated Thin Strut Sirolimus Eluting Stent Versus Durable Polymer Coated Everolimus Eluting Stent in Daily Clinical Practice: 1-Year Results from Interventional Cardiology Network Registry
Authors: Pawel Gasior, Marek Gierlotka, Krzysztof Szczurek-Katanski, Marcin Osuch, Lucjan Szela, Michal Hawranek, Andrzej Lekston, Mariusz Gasior, Lech Poloński
Journal: Journal of the American College of Cardiology (2016)
TCT-120 Primary angioplasty for patients over 75 years old in cardiogenic shock: contemporary results and prognostic predictors from the ESTROFA MI+75 nationwide registry
Authors: Jose M. de la Torre Hernandez, Salvatore Brugaletta, Joan Antoni Gomez Hospital, Jose Antonio Baz, Armando Perez de Prado, Ramon Lopez Palop, Ana Belen Cid Alvarez, Tamara Garcia Camarero, Alejandro Diego Nieto, Federico Gimeno, Jose Antonio Fernandez Diaz, Juan Sanchis Fores, Fernando Alfonso, Roberto Blanco, Javier Botas, Javier Navarro Cuartero, Jose Moreu Burgos, Francisco Bosa, Jose Miguel Vegas, Jaime Elizaga, Antonio Luis Arrebola Moreno, Jose R. Ruiz Arroyo, Felipe Hernandez, Neus Salvatella Giralt, Marta Monteagudo, Alfredo Gomez Jaume, Xavier Carrillo, Roberto Martin-Reyes, Fernando Lozano, Jose Rumoroso, leire andraka, Antonio J. Dominguez
Journal: Journal of the American College of Cardiology (2016)
TCT-505 Feasibility of a Novel Echo/X-Ray Fusion Software to Determine Implant Angulation during Transcatheter Aortic Valve Replacement
Authors: Kevin Sinclair, Daniel Bamira, Erin Girard, Michael Szucs, Ryan Spilker, Sammy Elmariah, Jonathan Passeri, Ignacio Inglessis
Journal: Journal of the American College of Cardiology (2016)
TCT-714 Incidental findings in Multislice CT for procedural planning in transcatheter aortic valve implantation: prevalence, clinical relevance and outcome
Authors: Teresa Trenkwalder, Anna Lena Lahmann, Costanza Pellegrini, Magdalena Nowicka, Tobias Rheude, N. Patrick Mayr, Sabine Bleiziffer, Ruediger Lange, Heribert Schunkert, Markus Kasel, Adnan Kastrati, Oliver Husser, Martin Hadamitzky, Christian Hengstenberg
Journal: Journal of the American College of Cardiology (2016)
P0231 : Effect of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma generated by hydrodynamic injection
Authors: M.N. Kim, S.W. Ro, Do Y. Kim, Da Y. Kim, J.H. Park, H.Y. Lim, K.-H. Han
Journal: Journal of Hepatology (2015)
Association Between Medicare Hospital Readmission Penalties and 30-Day Combined Excess Readmission and Mortality
Authors: Ahmad A. Abdul-Aziz, Rodney A. Hayward, Keith D. Aaronson, Scott L. Hummel
Journal: JAMA Cardiology (2016)

US hospitals receive financial penalties for excess risk-standardized 30-day readmissions and mortality in Medicare patients. Under current policy, readmission prevention is incentivized over 10-fold more than mortality reduction.To determine how penalties for US hospitals would change if policy equally weighted 30-day readmissions and mortality.Publicly available hospital-level data for fiscal year 2014 was obtained, including excess readmission ratio (ERR; risk-standardized predicted over expected 30-day readmissions) and 30-day mortality rates for heart failure, pneumonia, and acute myocardial infarction, as well as readmission penalties (as percent of Medicare Diagnosis Group payments). An excess mortality ratio (EMR) was calculated by dividing the risk-standardized predicted mortality by the national average mortality. Case-weighted aggregate ERR (ERRAGG) and EMR (EMRAGG) were calculated, and an excess combined outcome ratio (ECORAGG) was created by averaging ERRAGG and EMRAGG. We examined associations between readmission penalties, ERRAGG, EMRAGG, and ECORAGG. Analysis of variance was used to compare readmission penalties in hospitals with concordant (both ratios >1 or <1) and discordant performance by ERRAGG and ECORAGG.The primary outcome investigated was the association between readmission penalties and the calculated excess combined outcome ratio (ECORAGG).In 1963 US hospitals with complete data, readmission penalties closely tracked excess readmissions (r = 0.81; P < .001), but were minimally and inversely related with excess mortality (r = -0.12; P < .001) and only modestly correlated with excess combined readmission and mortality (r = 0.36; P < .001). Using hospitals with concordant ERRAGG and ECORAGG as the reference group, 17% of hospitals had an ECORAGG ratio less than 1 (ie, superior combined mortality/readmission outcome) with an ERRAGG ratio greater than 1, and received higher mean (SD) readmission penalties (0.41% [0.28%] vs 0.29% [0.37%]; P < .001); 16% of US hospitals had an ECORAGG ratio of greater than 1 (ie, inferior combined mortality/readmission outcome) with an ERRAGG ratio less than 1, and received minimal mean (SD) readmission penalties (0.08% [0.12%]; P < .001 for comparison with reference).In fiscal year 2014, financial penalties for one-third of US hospitals would have been substantially altered if 30-day readmission and mortality were considered equally important. Under most circumstances, patients would rather avoid death than rehospitalization. Current Medicare financial penalties do not meet the goals of aligning incentives and fairly reimbursing hospitals for patient-centered outcomes.
INTER-INDIVIDUAL DIFFERENCES IN THE RESPONSES OF VO <sub>2</sub> MAX TO PHYSICAL ACTIVITY COUNSELLING
Authors: P Williamson, G Atkinson, A Batterham
Journal: British Journal of Sports Medicine (2016)

Low cardiorespiratory fitness (VO 2max ) is an important risk factor for diabetes, cardiovascular disease and some cancers, making lifestyle interventions especially relevant. There is purported to be substantial inter-individual differences in how VO 2max responds to lifestyle/exercise interventions. Recently, we described the appropriate approach for quantifying these inter-individual differences. Therefore, we aimed to apply this approach to quantify inter-individual differences in the responses of VO 2max . We re-analysed data from the influential ‘Activity Counselling Trial’ (ACT), which was designed to determine the effects of general lifestyle assistance as well as formal counselling on physical activity and VO 2max in 479 men and 395 women. Importantly, an appropriate comparator group was also present in order to quantify ‘true’ inter-individual differences in VO 2max response. For women, the ‘true’ inter-individual responses in VO 2max (expressed as a SD) were found to be±129 (95% Confidence interval: −40 to 187) ml/min in the general lifestyle assistance group and±93 (−91 to 160) ml/min in the formal lifestyle counselling group. For men, true individual differences in response were±116 (95%CI: −130 to 210) ml/min and±148 (−105 to 234) ml/min in the assistance and counselling groups, respectively. Although the mean increase in VO 2max was greater in women, this increase corresponded to a trivial effect size. This application of the appropriate analyses to the ACT dataset indicate that, on average, the effects of activity counselling on VO 2max were small, although there were moderate ‘true’ inter-individual differences in the VO 2max response in women (0.34 SD) and small ‘true’ inter-individual differences in men (0.27 SD). Further genotype investigation may therefore be warranted in order to determine the mediators of this observed heterogeneity in response.
Diabetic microvascular triopathy, smoking, and risk of cardiovascular events – Author's reply
Authors: Jack R W Brownrigg, Cian O Hughes, David Burleigh, Alan Karthikesalingam, Benjamin O Patterson, Peter J Holt, Matthew M Thompson, Simon de Lusignan, Kausik K Ray, Robert J Hinchliffe
Journal: The Lancet Diabetes & Endocrinology (2016)
Integrating cancer genomic data into electronic health records
Authors: Jeremy L. Warner, Sandeep K. Jain, Mia A. Levy
Journal: Genome Medicine (2016)

The rise of genomically targeted therapies and immunotherapy has revolutionized the practice of oncology in the last 10–15 years. At the same time, new technologies and the electronic health record (EHR) in particular have permeated the oncology clinic. Initially designed as billing and clinical documentation systems, EHR systems have not anticipated the complexity and variety of genomic information that needs to be reviewed, interpreted, and acted upon on a daily basis. Improved integration of cancer genomic data with EHR systems will help guide clinician decision making, support secondary uses, and ultimately improve patient care within oncology clinics. Some of the key factors relating to the challenge of integrating cancer genomic data into EHRs include: the bioinformatics pipelines that translate raw genomic data into meaningful, actionable results; the role of human curation in the interpretation of variant calls; and the need for consistent standards with regard to genomic and clinical data. Several emerging paradigms for integration are discussed in this review, including: non-standardized efforts between individual institutions and genomic testing laboratories; "middleware" products that portray genomic information, albeit outside of the clinical workflow; and application programming interfaces that have the potential to work within clinical workflow. The critical need for clinical-genomic knowledge bases, which can be independent or integrated into the aforementioned solutions, is also discussed.
TCT-834 Bioresorbable Scaffolds versus Metallic Drug Eluting Stents – Comparison of Predicted Arterial Stress after Simulated Deployment in Concentric and Eccentric Coronary Lesions
Authors: Alessandro Schiavone, Chad Abunassar, Liguo Zhao, Syed Hossainy
Journal: Journal of the American College of Cardiology (2016)
Detection Of MYD88 L265P In Peripheral Blood Of Patients With Waldenström's Macroglobulinemia and IgM Monoclonal Gammopathy Of Undetermined Significance
Authors: Lian Xu, Zachary Hunter, Guang Yang, Yangsheng Zhou, Xia Liu, Yang Cao, Robert Manning, Christopher Patterson, Christina K Tripsas, Sandra Kanan, Jiaji G Chen, Neil I Lindeman, Steven Peter Treon
Journal: Blood (2013)
TCT-415 Absorb Bioresorbable Vascular Scaffolds vs. XIENCE Everolimus-Eluting Stents: Are Clinical Outcomes Different for Men and Women?
Authors: Dean Kereiakes, Stephen Ellis, Runlin Gao, Takeshi Kimura, Yoshinobu Onuma, Karine Piard-Ruster, Yunlong Zhang, Kai Koo, Patrick Serruys, Gregg Stone
Journal: Journal of the American College of Cardiology (2016)
TCT-575 Combined near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS) coronary imaging as a means to improve prediction of events by IVUS plaque burden alone
Authors: Jimmy Su, Cherry Greiner, Stephanie Grainger, Matthew Saybolt, William Pickering, Robert Wilensky, Joel Raichlen, Veronica He, Stephen Sum, James Muller, Sean Madden
Journal: Journal of the American College of Cardiology (2016)